Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Proteome SciencesCHIX:PRML Equity-to-Asset is -1.16 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Proteome Sciences ranks worse than 95.75% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Proteome Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2025 was £-9.53 Mil. Proteome Sciences's Total Assets for the quarter that ended in Dec. 2025 was £8.26 Mil.
Therefore, Proteome Sciences's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was -1.16.
The historical rank and industry rank for Proteome Sciences's Equity-to-Asset or its related term are showing as below:
CHIX:PRMl'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.16 Med: -0.36 Max: -0.02
Current: -1.16
During the past 13 years, the highest Equity to Asset Ratio of Proteome Sciences was -0.02. The lowest was -1.16. And the median was -0.36.
CHIX:PRMl's Equity-to-Asset is ranked worse than 95.75% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs CHIX:PRMl: -1.16
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Proteome Sciences Equity-to-Asset Related Terms
Proteome Sciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:PRML vs TMO, DHR, IDXX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Proteome Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Proteome Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteome Sciences (CHIX:PRML) has a Equity-to-Asset of -1.16 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Proteome Sciences and its competitors. According to the industry distribution chart, Proteome Sciences ranks #203 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 95.8%.
Is Proteome Sciences' Equity-to-Asset too high?
Proteome Sciences' current Equity-to-Asset is -1.16. Based on the distribution chart, Proteome Sciences ranks #203 out of 212 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Proteome Sciences' Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #203 out of 212 companies for Equity-to-Asset. This places Proteome Sciences in the lower half of its industry. The industry median Equity-to-Asset is 0.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Proteome Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteome Sciences's current Equity-to-Asset is -1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (CHIX:PRML) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.02, compared to a current price of £0.02 — trading 24.5% below its estimated fair value. The current Equity-to-Asset is -1.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Proteome Sciences (CHIX:PRML), the current Equity-to-Asset is -1.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PRML has been successfully added to your 
